Platelet function studies in myeloproliferative neoplasms patients with Calreticulin or JAK2V617F mutation
Alexandre Guy, Khalil Helzy, Olivier Mansier, Jean‐Claude Bordet, Étienne Rivière, Mathieu Fiore, Chloé James
Abstract
Background: -mutated blood platelets would have platelet function defects that might explain why these patients are at lower risk of thrombosis. Objectives: Our main objective was to explore and compare platelet function depending on the MPN molecular marker. Methods: mutation and compared them with healthy controls. None of these patients was taking antiplatelet therapy. We performed an extensive analysis of platelet function and measured plasmatic soluble P-selectin and CD40L levels. Results: . However, these results need to be interpreted within the context of absence of an inflammatory environment that could impact platelet function during MPN. Conclusions: .